Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (194)	11/6/1997 2:04:00 PM
From: bocaburgerman	Respond to of 3559

Rick, I think you are correct. NT-3 for gastro and BDNF for ALS. Regn stated that BDNF provided some sort of survival benefit for a "restrospectively -defined subset of ALS patients". As far as MZ's comment about Regn move out of neuro. My view is that this is entirely the work of Vagelos. CNTF, NT-3 and BDNF were already in the pipeline when Vagelos came aboard. We are seeing the company transform from one with scientific excellence to one with an effective product development program. IMO it is just a matter of time before the investment world views this company differently as well. Strong management, lots of cash, lots of potential. Winston

To: scaram(o)uche who wrote (194)	1/6/1998 10:41:00 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 3559

Rick and athers: Anyone who can put hand on this manuscript or at least abstract? >>Adv Pharmacol 1998;42:915-921 Cell body infusions of brain-derived neurotrophic factor increase forebrain dopamine release and serotonin metabolism determined with in vivo microdialysis. Altar CA, Fritsche M, Lindsay RM Regeneron Pharmaceuticals, Inc., Tarrytown, New York 10591, USA. PMID: 9328047, UI: 97468982<< Also, this abstract may add few candles on BDNF ambiguity: Nature 1997 Oct 23;389(6653):856-860 Anterograde transport of brain-derived neurotrophic factor and its rol in the brain. Altar CA, Cai N, Bliven T, Juhasz M, Conner JM, Acheson AL, Lindsay RM, Wiegand SJ Regeneron Pharmaceuticals, Inc., Tarrytown, New York 10591, USA. The role of neurotrophins as target-derived proteins that promote neuron survival following their retrograde transport from the terminals to the cell bodies of neurons has been firmly established in the developing peripheral nervous system. However, neurotrophins appear to have more diverse functions, particularly in the adult central nervous system. Brain-derived neurotrophic factor (BDNF), for example, produces a variety of neuromodulatory effects in the brain that are more consistent with local actions than with long-distance retrograde signalling. Here we show that BDNF is widely distributed in nerve terminals, even in brain areas such as the striatum that lack BDNF messenger RNA, and that inhibition of axonal transport or deafferentation depletes BDNF. The number of striatal neurons that contain the calcium-binding protein parvalbumin was decreased in BDNF+/- and BDNF-/- mice in direct proportion to the loss of BDNF protein, which is consistent with anterogradely supplied BDNF having a functional role in development or maintenance. Thus the anterograde transport of BDNF from neuron cell bodies to their terminals may be important for the trafficking of BDNF in the brain.<< mz